atezolizumab + epirubicin + cyclophosphamide

Atezolizumab + epirubicin + cyclophosphamide is a combination regimen used primarily in investigational and neoadjuvant treatment settings for breast cancer, especially in HER2-positive and triple-negative breast cancer. - **Atezolizumab** is a monoclonal antibody that targets programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor, thereby enhancing T-cell mediated immune response against tumor cells. - **Epirubicin** is an anthracycline chemotherapeutic agent that intercalates DNA, inhibits topoisomerase II, and generates free radicals, leading to cytotoxicity in rapidly dividing cells. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA and induces apoptosis. This regimen is used in clinical trials, commonly alongside other agents such as paclitaxel or platinum drugs, in the neoadjuvant (pre-surgical) treatment of breast cancer[1][3][5].